Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-Like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex) in Postmenopausal Patients With Advanced Hormono-Dependent Breast Cancer.

Trial Profile

Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-Like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex) in Postmenopausal Patients With Advanced Hormono-Dependent Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs AVE 1642 (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top